Novartis is trading 3.22% up at $159.52 as healthcare stocks rally broadly, with XLV up 3.23% during regular trading.

  • Investors are rotating toward healthcare amid stronger earnings expectations, favorable regulatory conditions, FDA approvals and increased sector M&A; Moderna’s positive cancer-vaccine results are lifting biotechnology sentiment.
  • Novartis announced 2026 ESC Congress cardiovascular data presentations; no direct company catalyst clearly explains the move. Shares are above the $154.55 recent close as the broader market is modestly higher, with no volume data identified.